Secure payment on i-micronews Contact Yole Développement for I Micronews reports

RSS I-micronewsYole Dévelopement on TwitterYole Développement on Google +LinkedIn Yole pageSlideshare Yole Développement I-Micronews

MedTech

Labcyte Inc. announced that it has entered an agreement with Merck, known as MSD outside the United States and Canada, to utilize Acoustic-Mass Spectrometry (Acoustic-MS) in drug discovery and development.Pioneered by Labcyte, acoustic droplet ejection (ADE) technology uses the gentle energy of sound waves to move liquids at nanoliter resolution with superior precision and accuracy. The technology does not contact the liquid in any way, avoiding the risk for sample loss, carryover or cross-contamination, and enables miniaturization with reliable fluid transfers at volumes as low as 2.5 nanoliters.

Read more ...

LivaNova PLC, a market-leading medical technology firm, announced it received CE Mark for its Vagus Nerve Stimulation Therapy® (“VNS Therapy”) System comprised of the SenTiva® generator and next-generation Programming System for the treatment of patients with drug-resistant epilepsy (“DRE”). LivaNova received FDA approval for the full VNS Therapy System in October 2017. The SenTiva generator offers the smallest and lightest responsive therapy with a number of new advanced features for the treatment of DRE. SenTiva is the only device of its size to include the AutoStim Mode, also known as Seizure Response Mode, which is designed to detect seizures and automatically deliver an extra dose of therapy.

Read more ...

Predicine announced that it has closed a $13.5 million Series A round of financing. Chinese venture capital firms Sangel Capital, Rongsheng Investment, and Highlight Capital participated in the round. Predicine said it will use the funding to advance the commercialization of its proprietary liquid biopsy technology, as well as its use in clinical trials, treatment selection, and cancer screening. The firm also intends to expand its cancer biomarker pipeline.

Read more ...

Initial Results from the Circulating Cell-Free Genome Atlas (CCGA) Study Support Feasibility of a Highly Specific Blood Test for Early Cancer Detection. GRAIL a life sciences company focused on the early detection of cancer, today announced initial results from its Circulating Cell-Free Genome Atlas (CCGA) Study. Data from three prototype genome sequencing assays showed it may be feasible to develop a blood test for early detection of multiple cancer types with greater than 99 percent specificity.

Read more ...

Twist Bioscience is enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that the company has expanded its presence in Asia Pacific, adding strategic distribution partners for synthetic DNA (genes, gene fragment, oligo pool product lines) as well as the exome and custom target enrichment product suite for next-generation sequencing. 

Read more ...

Analogic, a provider of leading-edge healthcare and security solutions, and Altaris Capital Partners, a leading private investment firm with expertise in Analogic’s end markets, today announced that Analogic and an affiliate of Altaris Capital Partners (together with certain affiliated entities, “Altaris”) have entered into a merger agreement under which Analogic will be acquired by Altaris for $84.00 per share in cash, or approximately $1.1 billion on a fully diluted basis. 

Read more ...

Upcoming Events


> Medical Wearables 2018
(May 16 - May 17, Santa Clara, California)

> Lab-on-a-Chip and Microfluidics Europe 2018
(June 5 - June 6, Rotterdam, The Netherlands)

Presentation

BioMEMS, the next big thing for MEMS players ?
Discover the presentation held by Sébastien Clerc at MEMS & Sensors Executive Congress, in ...
Status of the Microfluidics Industry
Discover the presentation held by Sébastien Clerc at Sensor China Conference of September 1...
Status of the Microfluidics Industry
Discover the presentation held by Benjamin Roussel at EAC Annual Conference 2017, in Singap...

Access to all our presentations